Surfing the MASH Tsunami
Driving the Discussion in Fatty Liver Disease. Join hepatology researcher and Key Opinion Leader Jörn Schattenberg, Liver Wellness Advocate Louise Campbell, and Forecasting and Pricing Guru Roger Green and a global group of Key Opinion Leaders and patient advocates as they discuss key issues in Fatty Liver disease, including epidemiology, drug development, clinical pathways, non-invasive testing, health economics and regulatory issues, from their own unique perspectives on the Surfing the MASH Tsunami podcast. #MASH #MAFLD #FattyLiver #livertwitter #AASLD #GlobalLiver #NoNASH #EASL
- Update frequency
- every day
- Average duration
- 26 minutes
- Episodes
- 1069
- Years Active
- 2020 - 2025
S2-E54 - Go Inside a Pivotal Event: the NASH Patient-Focused Drug Development Meeting
Global Liver Institute Founder, President and CEO Donna Cryer and her fellow patient and patient advocate Terri Milton join Stephen Harrison, Louise Campbell and Roger Green to review t…
S2-E53.3 - AASLD 2021 Preview: NASH Patient Management Topics Range From Drugs In Development To Applied Day-to-Day Issues
In the third conversation from SurfingNASH's AASLD 2021 preview, Manal Abdelmalek, Ken Cusi and Jörn Schattenberg join Louise Campbell and Roger Green to discuss a range of issues in t…
S2-E57.1 - 2021 TLMdX from AASLD: Putting a "Big, Fat Dent" in NAFLD and NASH
Manal Abdelmalek, Jörn Schattenberg and Ian Rowe join regulars Stephen Harrison, Louise Campbell and Roger Green to recap NAFLD and NASH-related insights from the 2021 TLMdX, the AASLD …
S2-E53.2 - AASLD 2021 Preview: A Weekend of Broad NASH Disease/Drug Management Coverage
In the second conversation from SurfingNASH's AASLD 2021 preview, Manal Abdelmalek, Ken Cusi and Jörn Schattenberg join Louise Campbell and Roger Green to discuss the breadth of NASH Dr…
S2-E53.1 - AASLD 2021 Preview: Presentations on Basic NASH Science
In the first conversation from SurfingNASH's AASLD 2021 preview, Manal Abdelmalek, Ken Cusi and Jörn Schattenberg join Louise Campbell and Roger Green to focus on some of the basic NASH…
S2-E53 - SurfingNASH Previews AASLD 2021: the Digital Liver Meeting
Manal Abdelmalek, Ken Cusi and Jörn Schattenberg join Louise Campbell and Roger Green to discuss key presentations at AASLD 2021 and preview SurfingNASH's coverage of the event. This vi…
S2-E52.4 - MRE Findings Suggest Flaws in Fibrosis As Endpoint
Alina Allen and Ian Rowe lead the Surfers in considering biopathological shortcomings in fibrosis as a solitary endpoint. Their comments stem from Alina's presentation of the recent Ma…
S2-E52.3 - Can MRE Provide Reliable, Non-Invasive Clinical Trial Endpoints?
Alina Allen and Stephen Harrison spearhead a discussion on how MRE results can provide a foundation for developing Subpart H Clinical Trial Endpoints from non-invasive testing data. The…
S2-E52.2 - How Liver Stiffness Measures Can Improve Practical Patient Management
Alina Allen and Ian Rowe discuss how Liver Stiffness Measurements (LSM) can improve individual patient treatment in pre-cirrhotic and compensated cirrhotic patients. Their comments stem…
S2-E52.1 - MRE Predicts Long-Term Progression and Outcomes in Chronic Liver Disease Patients
Alina Allen and Ian Rowe join the Surfers to discuss the recent Mayo Clinic paper, "MRE for Prediction of Long-Term Progression and Outcome in Chronic Liver Disease: A Retrospective Stu…
S2-E52 - Predicting Long-Term Outcomes Using MR Elastography
Professors Alina Allen and Ian Rowe join the Surfers to discuss our ability to predict long-term outcomes using MR Elastography. The conversation flows around Mayo Clinic's recent Hepat…
S2-E51.3 - More from Paris NASH: Overcoming Histopathology's flaws
The entire panel enters a discussion around histopathology's shortcomings, ranging from the fact that the NAFLD Activity score does not correlate with liver function to inconsistencies …
S2-E51.2 - More from Paris NASH: Precision Medicine's role in Drug Development and Patient Diagnosis
Stephen Harrison and Jörn Schattenberg join the conversation with questions that focus on patient treatment and drug development.
The ultimate payoffs from Precision Medicine will come i…
S2-E51.1 - More from Paris NASH: precision Medicine, Stellate Cells and Hepatic Influencers
Scott Friedman reprises key elements from his Paris NASH talk, focusing on Precision Medicine and some key factors that affect hepatic function that Precision Medicine must address.
Sco…
S2-E51 - Precision medicine, Fibrosis, Liver Function and the Future: a Discussion With Scott Friedman
Scott Friedman, the "Father of Fibrosis", and Jörn Schattenberg join the Surfers to discuss Scott's recent Paris NASH and National Liver Congress talks on Precision Medicine, imaging an…
S2-E50.3 - "Dare to Dream" - How New Imaging Methods Can Change Our Future
Antaros Medical's Chief Scientific Officer Lars Johansson joins Stephen Harrison, Louise Campbell, and Roger Green to reprise the key points of his recent Paris NASH talk. In this secti…
S2-E50.2 - "Seeing What Should Be" - Imaging the Liver To Assess Functioning Hepatocytes
Antaros Medical's Chief Scientific Officer Lars Johansson joins Stephen Harrison, Louise Campbell, and Roger Green to reprise the key points of his recent Paris NASH talk. This conversa…
S2-E50.1 - "Potential Game Changer" - Imaging Can Provide a Dynamic View of NASH Evolution
Antaros Medical's Chief Scientific Officer Lars Johansson joins Stephen Harrison, Louise Campbell, and Roger Green to reprise the key points of his recent Paris NASH talk. In this conve…
S2-E50 - "Dare to Dream" - the Exciting, Evolving World of Organ Imaging
Antaros Medical's Chief Scientific Officer Lars Johansson joins Stephen Harrison, Louise Campbell, and Roger Green to reprise the key points of his recent Paris NASH talk and comment on…
S2-E49.3 - Clinical Care Pathway: What Can Be Done Today?
Last author and leading endocrinology Fatty Liver Opinion Leader Ken Cusi joins co-author Stephen Harrison, Louise Campbell and Roger Green to discuss the recent Clinical Care Pathway p…